CM
SRDX

Castleark Management’s Surmodics SRDX Stock Holding History

Castleark Management’s Portfolio SRDX Stock Details SRDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-62,170
Closed -$2.94M – 401
2018
Q4 		$2.94M Sell
62,170
-8,790
-12% -$527K 0.13% 190
2018
Q3 		$5.3M Buy
+70,960
New +$4.89M 0.15% 192

Other funds holding SRDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Castleark Management's SRDX Position: Q1 2019 in Review

Castleark Management sold out of Surmodics (SRDX) in Q1 2019, closing a stake of 62,170 shares — an estimated $2.94M sold.

Castleark Management first reported a position in SRDX in Q3 2018 and held it in 2 quarters. The position peaked at $5.3M in Q3 2018. 151 funds tracked by Wall St. Rank hold SRDX as of Q1 2019.

  • Castleark Management reported no remaining Surmodics position as of Q1 2019 after selling out during the quarter.
  • Castleark Management sold 62,170 Surmodics shares in Q1 2019, an estimated $2.94M.
  • Castleark Management first reported a position in Surmodics in Q3 2018 and held it in 2 quarters.
  • Castleark Management's Surmodics position peaked at $5.3M in Q3 2018.
  • 151 funds tracked by Wall St. Rank held Surmodics as of Q1 2019.

Based on Castleark Management's 13F filing for Q1 2019, filed 14 May 2019.